Clin J Am Soc Nephro:新药Sofosbuvir:丙型肝炎治疗在肾病患者中

2017-09-30 白木清水 来宝网

一项新的研究表明,直接作用的抗病毒治疗在慢性肾脏疾病(CKD)和丙型肝炎病毒(HCV)感染患者中是安全有效的。美国肾脏病学杂志(CJASN)即将出版的研究报告也发现,治疗可能有助于改善一些患者的肾功能。

一项新的研究表明,直接作用的抗病毒治疗在慢性肾脏疾病(CKD)和丙型肝炎病毒(HCV)感染患者中是安全有效的。美国肾脏病学杂志(CJASN)即将出版的研究报告也发现,治疗可能有助于改善一些患者的肾功能。

HCV感染通常会引起慢性肾病患者的肝脏疾病,这增加了他们患肾衰竭的风险。Sofosbuvir是一种针对丙肝病毒的有效的直接抗病毒药物治疗,但是对潜在的肾脏毒性的担忧已经增加,尤其是在CKD患者身上。

为了确定sofosbuvir的安全性和有效性,Meghan Sise、MD(马萨诸塞州总医院)和她的同事们对98名患者进行了研究,他们在一个大的医疗系统中接受了基于sofosbuvird的治疗。

总体持续的病毒学应答(也就是治疗丙肝病毒感染的同义词)是81%,而在治疗过程中,平均肾功能是稳定的。与轻度慢性肾病患者相比,更先进的CKD患者更有可能治愈丙肝病毒感染。此外,在治疗后,有先进的慢性肾病患者,他们的肾功能也得到了改善。Sofosbuvir被合理地容忍了:不良事件是常见的(81%),但严重的不良事件(17%)和治疗不连续性(8%)是不常见的。此外,在不良事件发生率方面,CKD的程度也没有明显的影响。

需要进行更大规模的研究,以确定用直接抗病毒治疗的丙肝病毒根除是否会减缓或阻止慢性肾病患者在肾病和丙肝患者中晚期肾病的发展。

“在丙型肝炎感染患者中使用直接抗病毒治疗已经将疾病转化为可治愈的疾病。Sise说:“这项研究表明,这些药物可以安全有效地用于治疗1-3期肾脏疾病的患者。”

在一篇伴随的社论中,Richard Johnson,医学博士(科罗拉多大学)和Michiko Shimada,医学博士指出,还有其他的抗病毒药物对CKD和HCV的病人有效,而不像sofosbuvir,它们不会被肾脏所淘汰。因此,需要进一步研究不同抗病毒药物对肾功能损害的患者的影响。他们写道:“我们预测,丙肝病毒和艾滋病病毒等丙肝病毒将会慢慢消失,成为肾病患者的主要医疗问题。”

原始出处:

Meghan E. Sise, Elke Backman, Guillermo A. Ortiz, et al. Effect of Sofosbuvir-based Hepatitis C Virus Therapy on Kidney Function in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology (2017). DOI: 10.2215/CJN.02510317.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025822, encodeId=5a19202582283, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Apr 13 21:26:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274604, encodeId=fada12e460428, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500783, encodeId=f7001500e8395, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249248, encodeId=c586249248fa, content=已学习.值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Oct 01 00:18:41 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249155, encodeId=c00c249155cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Sep 30 19:01:19 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025822, encodeId=5a19202582283, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Apr 13 21:26:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274604, encodeId=fada12e460428, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500783, encodeId=f7001500e8395, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249248, encodeId=c586249248fa, content=已学习.值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Oct 01 00:18:41 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249155, encodeId=c00c249155cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Sep 30 19:01:19 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025822, encodeId=5a19202582283, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Apr 13 21:26:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274604, encodeId=fada12e460428, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500783, encodeId=f7001500e8395, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249248, encodeId=c586249248fa, content=已学习.值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Oct 01 00:18:41 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249155, encodeId=c00c249155cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Sep 30 19:01:19 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2025822, encodeId=5a19202582283, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Apr 13 21:26:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274604, encodeId=fada12e460428, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500783, encodeId=f7001500e8395, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249248, encodeId=c586249248fa, content=已学习.值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Oct 01 00:18:41 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249155, encodeId=c00c249155cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Sep 30 19:01:19 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2017-10-01 明天会更好!

    已学习.值得分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2025822, encodeId=5a19202582283, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Apr 13 21:26:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274604, encodeId=fada12e460428, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500783, encodeId=f7001500e8395, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Mon Oct 02 08:26:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249248, encodeId=c586249248fa, content=已学习.值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun Oct 01 00:18:41 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=249155, encodeId=c00c249155cb, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sat Sep 30 19:01:19 CST 2017, time=2017-09-30, status=1, ipAttribution=)]
    2017-09-30 131****1460

    学习了受益匪浅

    0

相关资讯

Ann Intern Med:新的检测方法可转变目前丙型肝炎病毒的检测

近日,据发表于Annals of Internal Medicine的一项系统性综述发现,几项新的检测方法可高度快速且灵敏的检测丙型肝炎病毒,且可将目前的两步法筛选过程转换成一步法。该综述将更新WHO关于丙型肝炎病毒筛查的指南。据统计,全球约有15000万人感染了丙型肝炎病毒,其中约3/4的患者来自低收入及中等收入国家。目前,丙型肝炎病毒的诊断分为两步,第一步是是检测丙型肝炎病毒的抗体,若为阳性,

PLoS One:中科院上海巴斯德所金侠研究组发表丙型肝炎病毒T细胞反应研究成果

2017年2月7日,国际知名学术期刊《PLOS ONE》在线发表了中国科学院上海巴斯德研究所金侠研究组和吉林大学第一医院牛俊奇研究组合作的最新研究成果

JCLA:三种不同丙型肝炎病毒基因分型方法的比较

基于遗传异质性,丙型肝炎病毒(HCV)被分为7个主要基因型和64个亚型。尽管序列存在一定的异质性,但是所有基因型在大开放阅读框架内共享相同的共线基因。这些基因之间的遗传相互关系在基因型之间是一致的。由于这一性质,其实并不需要对HCV基因组完整测序。 HCV基因型以及亚型分型对于抗病毒治疗至关重要,某些基因型还与肝硬化增加相关。

Medicine :HCV可能不是骨质疏松症发生的主要因素

丙型肝炎病毒暴露(HCV)对非晚期肝病患者骨密度的影响仍有争议。因此,研究者评估了HCV暴露和骨质疏松症发生的关系。从2000到2011,从纵向健康保险数据库2000识别年龄大于20岁的HCV暴露的患者。 共有51535个患者中,41228和10307的患者被归类为对照组和HCV暴露组。HCV暴露人群骨质疏松症的总发生率明显高于对照组(8.27 vs 6.19每1000人年;原始HR =  1.3

CCLM:比较两种丙型肝炎病毒基因分型的方法

丙型肝炎病毒(HCV)基因型可以作为治疗的预测指标。研究人员依次评估了两种核酸扩增试验(NAATs)和一种HCV基因型的血清学检测方法,包括Abbott RealTi me基因型II(RealTi me II),GeneMatrix限制性片段质量多态性(RFM)和Sysmex HISCL HCV Gr(HISCL Gr )。研究人员用三个检测方法检查了281个临床样本,使用HCV基因型性能亚组PH

NEJM:Sofosbuvir 及Velpatasvir治疗基因型1、2、4、5及 6的HCV感染患者的效果

采用简单的治疗方案以有效治疗长期感染丙型肝炎病毒(HCV)的患者,仍然是一个尚未满足的医疗需求。